Skip to main content
SpringerLink
Log in

Tumor lysis syndrome: pathogenesis and management

  • Practical Pediatric Nephrology
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Tumor lysis syndrome refers to the metabolic disturbances (hyperuricemia, hyperphosphatemia, hyperkalemia, and hypocalcemia) associated with lymphoproliferative malignancies which occur secondary to cell lysis. In some patients, tumor lysis results in acute renal failure. The nature and severity of the metabolic alterations are variable and may be influenced by the timing and intensity of chemotherapy, the magnitude of cell lysis, and the general condition of the patients with respect to hydration and glomerular filtration rate. Not only do hyperuricemia and hyperphosphatemia result from tumor lysis syndrome, they also contribute to oliguric acute renal failure in patients with tumor lysis. The pathogenesis of tumor lysis syndrome and current therapeutic strategies are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL (1980) Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med 68:486–491

    Google Scholar 

  2. Stapleton FB, Strother DR, Roy S III, Wyatt RJ, McKay CP, Murphy SB (1988) Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics 82:863–869

    Google Scholar 

  3. Kjellstrand CM, Campbell DC, von Hartitzsch B, Buselmeier TJ (1974) Hyperuricemic acute renal failure Arch Intern Med 133:349–359

    Google Scholar 

  4. Jones DP, Stapleton FB, Kalwinsky D, McKay CP, Kellie SJ, Pui C-H (1990) Renal dysfunction and hyperuricemia at presentation and relapse of acute lymphoblastic leukemia. Med Pediatr Oncol 18:283–286

    Google Scholar 

  5. Allon M, Llach F (1988) Hyperphosphatemia, hypocalcemia, and renal failure in a patient with acute leukemia. Am J Kidney Dis 11:442–445

    Google Scholar 

  6. Monballyu J, Zachee P, Verberckmoes R, Boogaerts MA (1984) Transient acute renal failure due to tumor-lysis-induced severe phosphate load in a patient with Burkitt's lymphoma. Clin Nephrol 22:7–50

    Google Scholar 

  7. Kaplan BS, Hebert D, Morrell R-E (1981) Acute renal failure induced by hyperphosphatemia in acute lymphoblastic leukemia. Can Med Assoc J 124:429–431

    Google Scholar 

  8. Band PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Banerjee TK, Little AS (1970) Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 283:354–357

    Google Scholar 

  9. Andreoli SP, Clark JH, McGuine, WA, Bergstein JM (1986) Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 109:292–298

    Google Scholar 

  10. Baldree LA, Stapleton FB (1990) Uric acid metabolism in children. Pediatr Clin North Am 37:391–418

    Google Scholar 

  11. Rieselbach RE, Bentzel CJ, Cotlove E, Frei E, Freireich EJ (1964) Uric acid excretion and renal function in the acute hyperuricemia of leukemia: pathogenesis and therapy of uric acid nephropathy. Am J Med 37:872–884

    Google Scholar 

  12. Mir MA (1977) Renal excretion of uric acid and its relation to relapse and remission in acute myeloid leukemia. Nephon 19:69–80

    Google Scholar 

  13. Emmerson Bryan T (1988) Hyperuricemia, gout, and the kidney. In: Schrier RW, Gottschalk CW (eds) Diseases of the kidney. Little Brown, Boston, pp 2481–2510

    Google Scholar 

  14. Kanfer A, Richet G, Roland J, Chatelet F (1979) Extreme hyperphosphatemia causing acute anuric nephrocalcinosis in lymphosarcoma. BMJ 1:1920–1921

    Google Scholar 

  15. Conger JD, Falk SA (1977) Intrarenal dynamics in the pathogenesis and prevention of acute nephropathy. J Clin Invest 59:786–793

    Google Scholar 

  16. Zusman J, Brown DM, Nesbit ME (1973) Hyperphosphatemia, hyperphosphaturia, and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 289:1335–1340

    Google Scholar 

  17. Ettinger DS, Harker WG, Gerry HW, Sanders RD, Saral R (1978) Hyperphosphatemia, hypocalcemia, and transient renal failure. JAMA 239:2472–2474

    Google Scholar 

  18. Cadman EC, Lundberg WB, Bertino JR (1977) Hyperphosphatemia and hypocalcemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemia. Am J Med 62:283–288

    Google Scholar 

  19. Holland P, Holland NH (1968) Prevention and management of acute hyperuricemia in childhood leukemia. J Pediatr 72:358–366

    Google Scholar 

  20. Masera G, Jankovic M, Zurlo MG, Locasciulli A, Rossi MR, Uderzo C, Recchia M (1982) Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 100: 152–155

    Google Scholar 

  21. Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD Hershfield MS (1988) Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 109:114–117

    Google Scholar 

  22. Davis S, Park YK, Abuchowski A, Davis FF (1981) Hypouricemic effect of polyethylene glycol modified urate oxidase. Lancet II: 281–283

    Google Scholar 

  23. Steinberg SM, Galen MA, Lazarus JM, Lowrie EG, Hampers CL, Jaffe N, (1975) Hemodialysis for acute anuric acid nephropathy. Am J Dis Child 129:956–958

    Google Scholar 

  24. Deger GE, Wagoner RD (1972) Peritoneal dialysis in acute uric acid nephropathy. Mayo Clin Proc 47:189–192

    Google Scholar 

  25. Bishof NA, Welch TR, Strife CF, Ryckman FC (1990) continuous hemofiltration in children. Pediatrics 85:819–823

    Google Scholar 

  26. Heney D, Essex-Cater A, Brocklebank JT, Bailey CC, Lewis IJ (1990) Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome. Pediatr Nephrol 4:245–247

    Google Scholar 

  27. Sakarcan A, Quigley R (1994) Hyperphosphatemia in tumor lysis syndrome: the role of hemodialysis and continuous veno-venous hemofiltration. Pediatr Nephrol 8:351–353

    Google Scholar 

  28. Saccente SL, Kohaut EC, Berkow RL (1993) Prevention of tumor lysis syndrome (TLS) using continuous veno-venous hemofiltration. J Clin Oncol 11:252a

    Google Scholar 

  29. Maher JF (1989) Pharmacologic consideration for renal failure and dialysis. In: Maher JF (ed) Replacement of renal function by dialysis, 3rd edn. Kluwer, Dordrecht, pp 1018–1076

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Tennessee, Memphis, LeBonheur Children's Medical Center, 50 North Dunlap, Room 301, 38103, Memphis, Tennessee, USA

    Deborah P. Jones & Russell W. Chesney

  2. Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA

    Hazem Mahmoud

  3. Center for Pediatric Pharmacokinetics and Therapeutics, Pediatric Pharmacology Research Unit, Crippled Children's Research Foundation, Memphis, Tennessee, USA

    Deborah P. Jones & Russell W. Chesney

Authors
  1. Deborah P. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hazem Mahmoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Russell W. Chesney
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, D.P., Mahmoud, H. & Chesney, R.W. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 9, 206–212 (1995). https://doi.org/10.1007/BF00860751

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00860751

Key words

Search

Navigation